Αρχική World News Talquetamab Continues To Demonstrate High Overall Response Rates in Heavily Pretreated Patients... World News Talquetamab Continues To Demonstrate High Overall Response Rates in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma Από Ogkologos - 1 Απριλίου, 2025 914 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MonumenTAL-1 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Cetuximab Outperforms Durvalumab for Head and Neck Cancer When Cisplatin Isn’t... 19 Δεκεμβρίου, 2024 Keanu Reeves Has A Long History Of Supporting Cancer Research 13 Ιανουαρίου, 2022 Preventing Chemo Brain? Study Identifies Potential Approach for Common Problem 2 Νοεμβρίου, 2022 Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic... 27 Ιανουαρίου, 2025 Φόρτωση περισσοτέρων HOT NEWS Some Women Avoid Breast Cancer Screening After False-Positive Mammogram Results FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer Safety Analysis Shows that Durvalumab Treatment After SBRT Is Feasible in... Pembrolizumab Now Second Immunotherapy Approved to Treat Merkel Cell Carcinoma